Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVVU4V)

Drug Name
SLN360 Drug Info
Indication
Disease Entry ICD 11 Status REF
Hyperlipidemia 5C80.Z Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMVVU4V

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Apolipoprotein A messenger RNA (LPA mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pelacarsen DMY757D Cardiovascular disease BA00-BE2Z Phase 3 [3]
ISIS-APO(a) DMQ3C05 Coronary artery disease BA80 Phase 2 [4]
AMG 890 DM3H0IX Cardiac fibrosis DB98.8 Phase 2 [5]
LY3819469 DMUDNNF Elevated Lipoprotein(a) 5C80.1 Phase 2 [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Apolipoprotein A messenger RNA (LPA mRNA) TTU9LGY APOA_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT05537571) A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Investigate Efficacy, Safety and Tolerability of SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events. U.S.National Institutes of Health.
2 Recent lipoprotein(a) trials. Curr Opin Lipidol. 2022 Dec 1;33(6):301-308.
3 Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. JAMA Cardiol. 2022 Jul 1;7(7):760-769.
4 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
5 Clinical pipeline report, company report or official report of Amgen.
6 ClinicalTrials.gov (NCT05565742) A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults With Elevated Lipoprotein(a). U.S.National Institutes of Health.